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Gerald A. Colvin,1 David Berz,1 Muthalagu Ramanathan,2 Eric S. Winer,1 Loren Fast,1
Gerald J. Elfenbein,3 Peter J. Quesenberry1Allogeneic bone marrow transplantation relies on immunosuppression, which controls graft-versus-host
disease (GVHD) and allows engraftment at the expense of diminished graft versus-tumor (GVT) activity. Ad-
vances in hematologic transplantation have prompted the development of effective, less-toxic regimens that
attempt to balance GVH and GVT immunoreactions. We analyzed the safety and efficacy of haploidentical
transplantation in a Phase I/II nonimmunosuppressive, nonmyeloablative setting. A total of 41 patients
with relapsed refractory cancer received 100 cGy of total body irradiation (TBI), along with an infusion of
1  106 to 2  108 CD31 cells/kg; 29 patients received the highest dose. A postinfusional cellular graft re-
jection syndrome resembling engraftment syndrome was noted at the 2 highest CD31 infusion cohorts.
There were 26 patients with hematologic malignancies with 14 responses, 9 of which were major. Two of
6 patients with lymphoma remained free of disease at 76 months and 82 months, respectively; there were
5 durable complete responses and 4 partial responses in 13 patients with acute myelogenous leukemia
(AML). All responses occurred outside of donor chimerism. TBI at 100 cGy followed by HLA-haploidentical
immunotherapy is a biologically active therapy for patients with refractory AML and lymphoma. Possible
mechanisms contributing to its effectiveness include initial GVT kill, breaking of host tolerance to tumor
through cross-reactive alloreactive responses, persistent nondetectable microchimerism, or some combina-
tion of these.
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Immunologic destructionof cancer dates back to the
18th centurywith the observation that certain infectious
disease processes confer a beneficial therapeutic effect
on malignancy. In the early 20th century, some cancer
patients demonstrated complete tumor regression after
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6/j.bbmt.2008.12.503workers [1-3] used endotoxin from heat-killed strepto-
cocci and Serratia marcescens as a vaccine to treat more
than 300 patients. Overall response rates were 63% in
patientswith sarcomaand52%in thosewith lymphoma,
with durable responses (many life-long) seen in52%and
38%, respectively.Allogeneic bonemarrow transplanta-
tion (alloBMT)has turnedout tobe anotherpotent form
of immunotherapy.There is ample evidence that a graft-
versus-tumor (GVT) effect exists with donor lympho-
cyte infusion (DLI) in patients with chronic myeloge-
nous leukemia (CML) and those with graft-versus-host
disease (GVHD) [3-6].
A critical role of alloBMT is to administer immu-
noregulatory cells to eradicate residual malignancy
and prevent recurrences. It was once thought that
high-dose therapy was necessary to eradicate host mar-
row stem cells and open up niches (extravascular sites of
marrow hematopoiesis) to allow cell expansion; how-
ever, various studies have demonstrated that successful
engraftment can occur in both nontreated hosts [7-11]
and minimally treated hosts [12-14]. The key factor is
the infusion of high numbers of donor cells to compete
with residual hostmarrow. Stewart et al. [14] found that421
Table 1. Patient Disease and eligibility Characteristics
(n 5 41)
Diagnosis Eligibility
Solid tumors (n 515)
Breast 3 Refractory/active malignancy
Renal cell 3 Age >3 months
Bladder 2 Expected survival? 3 months
Ewing’s sarcoma 2 HL-3/6 related donor
Eccrine 1 Bilirubin < 2.0 mg/dL
Lung 1 No uncontrolled infections*
Melanoma 1 HIV negative
Prostate 1 DLCO > 40%
Head and neck 1 LVEF > 35%
Hematologic malignancies (n 5 26) MMSE > 20 if age > 75 years
AML 13
NHL 6
Multiple myeloma 5
Acute Lymphoblastic leukemia 1
Chronic Myelogenous leukemia 1
DLCO indicates diffusing capacity of the lung fot carbon monoxide;
LVEF, left ventricular ejection fraction; AML, acute myelogenous leuke-
mia; HL, hodgkin lymphoma; NHL, non-hodgkin lymphoma; MMSE,
Mini mental status exam.
*Any fungal infection had to be responsive to anti-fungal therapy and
treated for longer than 1 month.
422 Biol Blood Marrow Transplant 15:421-431, 2009G. A. Colvin et al.host marrow eradication was unnecessary and that syn-
geneic marrow could be transplanted into nontreated
or minimally treated (100 cGy) mice, resulting in the
establishment of long-term, multilineage chimerism.
A total body irradiation (TBI) dose of 100 cGy resulted
in high levels of donor chimerism with a reduction in
host stem cell function to only 8.6% of the baseline
level, while preserving host hematopoiesis. Final chi-
merism is based primarily on stem cell competition in
the syngeneic setting [15]. These initial studies led to
cellular immune therapy trials in which preparative
treatment was minimized and immunocompetent
T cell numbers were maximized.
In previous work [16], we infused T cell–replete
HLA-matched peripheral blood (1  108 CD31 cells/
kg) from nonmobilized donors into patients with re-
fractory hematologic malignancies treated with 100
cGy of TBI. Nine of 11 patients achieved mixed or
complete donor chimerism, and 5 (55%) developed sig-
nificant acute GVHD (aGVHD), resulting in 1 death.
Remarkably, 4 complete responses (CRs) occurred,
2 of which (lymphoma and relapsed acutemyelogenous
leukemia [AML]) were of long duration. In addition,
several patients had aCRwhile achieving only transient
chimerism.One patient who achieved 5%chimerism at
week11 after infusion remained disease-free for more
than 10 years after transplantation [16].
In the aforementioned study,many eligible patients
were untreated because of the lack of anHLA-identical
matched sibling donor. Approximately 95%of patients
have HLA-haploidentical relatives, however. Conven-
tional high-dose,HLA-haploidentical immunotherapy
is limited by toxicity, especially GVHD, but may exert
potent GVT effects with the infusion of immunocom-
petentT or natural killer (NK) cells because of the hap-
lodisparity between donor and host [17-21]. aGVHD
can be reduced by T cell depletion, but this also abro-
gates the GVT effect [22-28] and increases rejection
and infections [29,30].
Conventional dogma holds that sustained chime-
rism/engraftment is necessary for prolonged responses;
however, our previous study found a long-term re-
sponse with transient chimerism, suggesting that it is
not required for a therapeutic effect. In the present
Phase I/II study,wedetermined recipient response rates
with HLA-haploidentical donors while infusing vary-
ing numbers of granulocyte colony-stimulating factor
(G-CSF)- primed cells. G-CSF was used to polarize
the T cells to a Th2 phenotype, to minimize GVHD
in the event of engraftment [31-33]. The risk of graft re-
jection was increased because of HLA disparity [34].MATERIALS AND METHODS
All patients were enrolled on a protocol approved
by the Roger Williams Medical Center’s Institutional
Review Board and Radiation Safety Committee.Disease and eligibility characteristics are outlined in
Table 1.Cell Collection Protocol
Initially, as a safety procedure, the first 10 patients
underwent autologous peripheral blood stem cell
(PBSC) apheresis and cell storage before transplanta-
tion. This was performed in case we needed to eradi-
cate the graft because of GVHD. It was later
discontinued because of lack of GVHD and engraft-
ment.
Related HLA-haploidentical donors were given
G-CSF (16 mg/kg/day) for 5 days, after which they un-
derwent leukapheresis. If the donors needed additional
CD31 cells, they were given G-CSF (16 mg/kg) 1
hour before the second leukapheresis. Thirty donors
(73%) underwent leukapheresis over 2 days, and 11
(27%) did so over 1 day.Conditioning
Patients were treated with 100 cGy of TBI given by
lateral opposing fields at a rate of 10 to 15 cGy/min
using a linear accelerator (25 MV). Variations in the
absorbed dose were within\ 10% of the dose to the
prescription point throughout the body, with excep-
tion of the superficial 2 mm and the lungs. Beam
spoilers of low-density plastic were used to achieve
a more homogeneous surface dose. The collimator
opening and treatment distance was such that the pa-
tient was entirely within the treatment beam without
extension into the penumbra region. Individual pa-
tient-specific compensators (bolus material) provided
X-ray dose uniformity; no shielding was provided.
Biol Blood Marrow Transplant 15:421-431, 2009 423HLA-Haploidentical Cellular ImmunotherapyTBI was administered in the morning, and the leuka-
pheresis product was given 6 hours later.
Cell Administration
The entire leukapheresis product was used. The
cellular components were identical to those obtained
by standard leukapheresis. T cell and CD341 concen-
trations were obtained, with the volume of product ad-
ministered depending onTcell dose level.The patients
were divided into 5 cohorts based ondose level: 1 106,
1  107, 3  107, 1  108, and 2  108 CD31 cells/kg.
Four patients were treated at each of the 3 lowest T cell
dose levels, 8 patients were treated at the 1 108 level,
and 21 patientswere treated at the 2 108 level, consid-
ered the maximum tolerated dose. Another 4 patients
were added to the 1  108 dose level in accordance
with protocol because of grade IV treatment toxicity
in 1 of the first 4 patients.
G-CSF–mobilized donor CD341 cells (mean
dose, 4.9  106/kg) were infused along with escalating
doses of CD31 cells (1 106 to 2 108/kg) after 100
cGy of TBI. The unprocessed cells were administered
6 hours after TBI on the same day as leukapheresis was
performed. Cyclosporine (CsA; Neoral; Novartis,
Basel, Switzerland) 6.25 mg/kg twice daily by mouth
was started on day 0 for patients given CD31 cells at
1 106 and 1 107. No response was seen in those
patients who received cyclosporine. CsA therapy was
discontinued 4 weeks after initiation, once the absence
of chimerism was confirmed.
Chimerism Analysis
In the first 20 patients, blood chimerism analysis
done 2 weeks after transplantation revealed no detect-
able chimerism as determined by short-tandem repeats
[16]. Because no chimerism was detected initially, we
performed evaluations at earlier time points, including
1, 2, 3, 6, 14, and 21 days (in addition to the foregoing
time points) after initial cell infusion, to explore the ki-
netics of rejection. We concomitantly evaluated serial
marrow chimerism in a subset of patients with AML.
The reproducible level of sensitivity in our assay, as
monitoredbycontrolmixture lanes,was 1%to5%.Per-
cent donor engraftment or chimerismwas definedas the
percentage of total cells derived from donor DNA.
Haploimmunostorm Cytokine Analysis
The serum samples were stored in a freezer at
280Cuntilmultiplex cytokine analysiswas conducted
using the Human 17-Plex Panel Cytokine Assay and
the Bio-Plex Suspension Array System (Bio-Rad)
according to the manufacturer’s instructions.
Statistical Analysis
Primary endpoints included Phase I toxicity and
Phase II response rates. Secondary apriori endpoints in-cluded response duration, chimerism, and toxicity. We
expected accrual of 25 patients for the Phase II compo-
nent. Sample size calculation was based on the primary
endpoint of response rate. The null hypothesis was a re-
sponse rate (CR1 partial response [PR])\ 1% versus
the alternative hypothesis with a response rate $ 10%.
With 25 patients, the study had 80% power with a 2-
sided significance level of .05 to detect this difference.
(All P values were 2-sided.) Objective measurements
included restaging tests conducted beginning 30 days
before therapy and continuing through day 100 after
therapy. Disease (hematologic malignancy vs solid tu-
mor), T cell dose, GVHD development, previous che-
motherapy, neutropenia, and number of platelet/red
blood cell (RBC) transfusionswere studied as predictive
factors for donor chimerism, tumor response, and toxic-
ity. The nonparametric Spearman’s rank correlation
coefficient was used to assess the correlation between
CD31 dose and survival by diagnosis (hematologic vs
solid tumor). All statistical analyses were done using
Stata 6.0 (StataCorp, College Station, TX).Role of the Funding Source
The study sponsors had no role in study design,
data collection, data analysis or interpretation, the
writing of this manuscript, or the decision to submit
the manuscript for publication.RESULTS
Patient Characteristics
A total of 41 patients with refractory malignancies
were enrolled into this Phase I/II protocol between
June 2001 and March 2005. Median patient age was
58 years (range: 16 to 82 years). Human Research Re-
viewCommittee approval was obtained before patients
were enrolled. Disease distribution among the patients
is outlined in Table 1, and previous chemotherapy is
described in Appendices 1 and 2. Six patients had pre-
vious autologous BMT, including 2 with breast cancer
(5 months and 18 months earlier), 2 with lymphoma
(8 months and 6 years earlier), 1 with myeloma (3 years
earlier), and 1 with Ewing’s sarcoma (4 months ear-
lier). The median interval between autologous BMT
and haplotransplantation was 25 months (range, 4 to
75 months), the median time from diagnosis to haplo-
transplantation was 21 months (range, 2 to 111
months), and the median number of previous treat-
ment regimens was 3 (range, 0 to 7).
Median donor age was 41 years (range, 20 to 88
years). The group comprised 22 men and 19 women.
A total of 17 donor–recipient pairs were sex-
mismatched, and 1 patient who died of presumed
GVHD was sex-mismatched.
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Figure 1. Hematopoietic kinetics and toxicity: patient cell counts. (A) Median WBC count, ANC, and platelet count of patients with hematologic
(n 5 26) and solid tumor (n 5 15) malignancies at various times after transplantation. (B) Treatment-related toxicity of all patients graded according
to Eastern Cooperative Oncology Group criteria using a toxicity array. Each patient is represented from left to right, with the patient number listed
on the top of the array and each toxicity grade depicted in vertical columns. Because many patients already had grade 4 toxicity resulting from their
disease, the grade of toxicity deviation from baseline is presented, to show actual treatment-related toxicity.
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Table 2. HIS Characteristics in the 30 Patients in the 1  108
to 2  108 CD3 + Cells/kg Cohorts
Hyperpyrexia, day 0 to 1 (100%) Median onset, 14 hours
100% resolution by 6 hours with steroid
administration
(Steroids administered for hyperpyrexia
lasting >72 hours)
Malaise (100%) Seen in 30 of 30 patients
LFT aberration (93%) Seen in 28 of 30 patients
Morbilliform rash (60)% Seen in 18 of 30 patients
Diarrhea (73%) Seen in 22 of 30 patients
Skin and colon biopsies No acute GVHD
GVHD, graft-versus-host disease.
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Figure 1A shows blood count changes in the pa-
tients with hematologic malignancies. During the first
8 weeks, the patients had an absolute neutrophil count
(ANC)\1000 lasting a median of 37 days (range, 10 to
64 days) and an ANC\500 lasting amedian of 27 days
(range, 23 to 50 days). The mean ANC nadir was 340
on day134. A bimodal mean distribution of the white
blood cell (WBC) count and ANC was noted, with an
initial drop by day115, improvement by day121, and
then a second drop by day134. The patients with solid
tumors generally had aWBC count (median, 7.5 k/mL)
and ANC (median: 5562) within normal ranges before
treatment. The mean ANC never dropped below 500,
with a nadir of 893 at day 132. Hemoglobin and he-
matocrit levels remained stable with blood transfusion
support. Other toxicities are shown in Figure 1B.
In the 26 patients with hematologicmalignancies de-
pendencyonbloodproducts increasedfrom1to2months
beforeBMTto after BMT.RBC transfusion dependence
increased from 80% (21 of 26) to 89% (23 of 26), and
platelet dependence increased from 89% (23 of 26) to
92% (24 of 26). Seventeen of the 26 patients became
transfusion-independent by day 100 after BMT.
Infusion-Related Syndrome
An acute clinical syndrome known as a ‘‘haplo im-
munostorm’’ (HIS) was observed after haplotransplan-
tation, likely occurring secondary to cytokine flux. HIS
represents neither hyperacute nor aGVHD, but rather
is a syndrome comprising 1 or more symptoms, as out-
lined in Table 2. Examples of the skin rash and biopsy
findings inHIS are shown in Figure 2, and serial serum
multiplex cytokine level measurements are depicted in
Figure 3. In the 2 108 CD31 cell/kg cohort (n5 17),
significant elevations (P\ .05) between pretransplan-
tion and posttransfusion levels were found in interleu-
kin (IL)-6, IL-8, IL-10, interferon (IFN)-g, IL-5,
IL-7, IL-13, monocyte chemoattractant protein
(MCP)-1, and macrophage inflammatory protein
(MIP)-1b. No significant changes were seen in IL-2,
IL-4, granulocyte-macrophage colony-stimulating
factor (GM-CSF), INF-a, IL-1b, IL-7, IL-12, IL-17,
or granulocyte colony-stimulating factor (G-CSF).
This cytokine profile is unlike any reported previously
and is separate from GVHD and engraftment syn-
drome.
Chimerism and aGVHD
The presence of chimerism was initially assessed at
2-week intervals, but because no evidence was found,
we examined earlier time points after cell infusion. In
most of the patients in the highest CD31 dose cohort
(2 108/kg CD31), transient donor chimerism was
seen in the blood or marrow, but disappeared by
14 days; . 5% chimerism was observed in 10 of 29patients given cells (Table 3). Two patients converted
to full donor chimerism (100%) by 24 and 28 days after
cell infusion; one of these patients had active lym-
phoma, but developed severe aGVHD that was
responsive to corticosteroids and died from polymi-
crobial sepsis, and the other died from disease progres-
sion (metastatic breast cancer) as noted on autopsy.
This latter patient had undergone autologous BMT
18 months earlier, after which she developed mixed
chimerism of 12.5% at 2 weeks and full chimerism
(100%) at 24 days. She died 24 days after undergoing
haplotransplantation from progressive disease with
biopsy results negative for aGVHD.
The 8 patients treated with 1  106 or 1  107
CD31 cells/kg demonstrated no response. One patient
with metastatic breast cancer treated with 1 107
CD31 cells/kg had stable disease without therapy for
7 months before progression was noted.
Of the 31 patients who received higher CD31
doses, objective responses were seen in 14 patients
withhematologicmalignancies (5CR, 2PR, and7 tran-
sient response), and stable disease was seen in 1 patient
with renal cell cancer. Three patients could not be eval-
uated because they died of other causes within a month
of transplantation. Twenty-three patients exhibited
disease progression, including 13 of 15 patients with
solid tumor malignancies and 10 of 26 patients with
hematologic malignancies. Interestingly, all of the re-
sponses were seen in the leukemia and lymphoma sub-
group, and no responses were seen in the multiple
myeloma (MM) subgroup.
Four of 6 patients with relapsed, refractory B cell
non-Hodgkin lymphoma (NHL) had a response (2 PR
and 2 CR). The 2 patients with a CR had diffuse large
cell lymphoma (DLCL) and lymphoblastic lymphoma,
respectively, and were 76 and 82 months out of treat-
ment, respectively, at the time of this writing. Serial
computed tomography (CT) scans from the patient
with DLCL showed a large volume abdominal tumor
burden that continued to shrink despite lack of detect-
able chimerism or any further therapy (Figure 4A).
Both patients with PR underwent subsequent autolo-
gous BMT, 1 at 112 days and the other at 380 days
from haplotransplantation. The first patient, who had
Figure 2. HIS characteristics: an example of skin changes with the syndrome. (A) Day 4 after cell infusion. (B) Day19. (C) Histological section obtained
on day 4 showing spongiosis and lymphocyte invasion with no evidence of GVHD.
426 Biol Blood Marrow Transplant 15:421-431, 2009G. A. Colvin et al.DLCL, had previously stored marrow cells and under-
went transplantation because of persistent pancytopenia
and residual disease. This patient converted to CR after
autologous BMT, with a return to normal counts. The0
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Figure 3. Multiplex cytokine analysis of serum. Cytokine levels were
measured using the Human 17-Plex Panel Cytokine Assay (IL-1, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 [p70], IL-13, IL-17, G-CSF, GM-CSF,
IFN-g MCP-1 [MCAF], MIP-1b, TNF-a) and the Bio-Plex Suspension
Array System (Bio-Rad) according to the manufacturer’s instructions.
The results were compared against a standard curve derived from
recombinant cytokine standards ranging from of 0.2 to 3200 pg/mL.
Cytokine concentrations were calculated using Bio-Plex Manager soft-
ware (Bio-Rad). The data are presented in pg/mL. Serial serum samples
were obtained in 17 patients at the 2 108 CD31 cell/kg level. Cytokine
levels were evaluated immediately before any therapy and then after cell
infusion in patients with HIS during fever spikes. Significant elevations
(P\.05) in the 2  108 CD31 cell/kg cohort (n 5 17) between prein-
fusion and postinfusion values were seen in IL-6 (264 6 61 vs 3757 6
1308 pg/mL), IL-8 (21 6 7 vs 77 6 18 pg/mL), IL-10 (5 6 1.7 vs
91618.6 pg/mL), IFN-g (3.7 6 3.0 vs 30.9 6 6.4 pg/mL), IL-5 (1.28 6
0.49 vs 11.0 6 2.7 pg/mL), IL-7 (3.7 6 1.4 vs 7.7 6 1.1 pg/mL), IL-13
(0.51 6 0.28 vs 4.2 6 1.0 pg/mL), MCP-1 (87.1 6 25.4 vs 1188.7 6
773 pg/mL), and MIP-1b (94.9 6 18.5 vs 999.8 6 773.8 pg/ml). No sig-
nificant elevation or depression of IL-2, IL-4, GM-CSF, INF-a, IL-1b, IL-7,
IL-12, IL-17, or G-CSF occurred.patient succumbed tocytomegalovirus (CMV)pneumo-
nia 10months later, but was free of lymphoma.The sec-
ond patient, who had transformed follicular lymphoma
(FL), had significant cardiomyopathy at the time of tu-
mor recurrence, which prohibited autologous trans-
plantation. This patient had a PR and underwent
palliative therapy with rituximab and radiation to the
main tumor bed. Although tumor shrinkage occurred,
active disease persisted. The patient’s cardiac function
normalized, and autologous transplantation converted
her to CR. She succumbed to refractory Babesiosis infec-
tion 56months after haplotransplantation, free of recur-
rent lymphoma.
Encouraging responses were seen in several pa-
tients with refractory AML; 3 of 13 patients obtained
durable CR lasting 8, 11, and 31 months, respectively.
The first patient died free of disease (as documented
1 week before death) from preexisting arteriovenous
malformation bleeding complications. In the second
patient, who had an underlying myelodysplastic syn-
drome (MDS), the leukemic clone was eliminated
but residual myelodysplasia remained. The MDS had
clonal evolution with recurrent or new AML develop-
ing 11 months after haplotransplantation. The patient
declined further treatment. The third patient had re-
lapsed, refractory active promyelocytic leukemia with
a new chromosomal abnormality of 1:12. He demon-
strated CR for 31 months after haplotransplantation,
after which the disease recurred. He was brought
into CR with arsenic trioxide and, after a second hap-
lotransplantation, was disease-free at 38 months after
his last treatment. Transient responses, defined as per-
sistent loss of peripheral blood blasts and/or.50% re-
duction in marrow blasts on restaging of bone marrow
2 weeks after transplantation, were seen in 7 of 12
evaluable patients. These responses lasted a median
of 19 6 5 days. Three of these patients demonstrated
improved blood counts, and 6 demonstrated improved
performance status. All responses occurred at CD31
cell doses of 1 to 2  108 cells/kg and in the absence
of measurable donor chimerism (\ 5%). Serial bone
Table 3. Therapeutic Response and Cell Dose Effect
Macrochimerism: 2 Weeks to 2 Months (> 5%)
All patients 5% (2 of 38)
AML responders 0% (0 of 10)
NHL responders 0% (0 of 4)
Two patients engrafted; 1 died of infection complications, and the other died
from acute GVHD. Three patients died on day 6-9 and were not evaluable for
chimerism
Clinical Response
AML NHL Solid Tumors
CR 23% (3 of 13) 33% (2 of 6) 0% (0 of 15)
PR 0 33% (2 of 6) 0% (0 of 15)
Transient response 54% (7 of 13) 0 0% (0 of 15)
Stable disease 0 0 13% (2 of 15)
Total response 77% (10 of 13) 66% (4 of 6) 0% (0 of 15)
Cell Dose
and Response
Dose Level
Number
of Patients Response Disease
1  106 CD3+ cells/kg 4 0
1  107 CD3+ cells/kg 4 0
3  107 CD3+ cells/kg 4 2 (stable disease) Renal, breast
1  108 CD3+ cells/kg 8 2 NHL (PR), AML (CR)
2  108 CD3+ cells/kg 21 10 NHL, AML
AML indicates acute myelogenous leukemia; NHL, non-hodgkin lym-
phoma; GVHD, graft-versus-host-disease; CR, complete response; PR,
partial response.
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showed evidence of large tumor reduction and early
resumption of normal hematopoiesis (Figure 4B).
Although the radiation therapy possibly could have eli-
cited some transient antitumor response, our murine
models demonstrated no change in marrow cellularity
9 days after 200 cGy of TBI (data not shown). (We
used 200 cGy instead of 100 cGY, because the LD50Figure 4. Antitumor effects and distribution kinetics of infused cells. (A) Seria
phoma who remained in complete remission 60 months after haploidentical i
tumor regression over time. The most recent restaging with PET/CT scan perf
(B) Transient response to haplo immunotherapy as demonstrated by represen
cell infusion, a marked response to therapy is evident, with loss of myelobla
hematopoiesis is seen, but by 26 days after therapy, the leukemia has returnedin mice is approximately double that in humans.)
Figure 3C illustrates the kinetics of graft rejection.
Except for the 2 patients who engrafted, no patients
exhibited detectable chimerism by 3 weeks after haplo-
transplantation.DISCUSSION
Nonengrafting haploidentical transplantation
with minimal myeloablation (100 cGy) is an appro-
priate therapeutic strategy for older patients with
significant comorbidities, and it provides a virtually
universal donor pool. Side effects include well-tolerated
myelotoxicity and an immediate postransplantation
steroid-responsive immunologic syndrome. Significant
antitumor responses, some complete and long-lasting,
were seen in patients with leukemias and lymphomas
in the absence of stable chimerism. Tumor responses
occurred both early and late after haplotransplantation,
with the most pronounced immediate antitumor res-
ponses seen in the patients with leukemias.The patients
with lymphomas tended to experience continued tumor
regression, as demonstrated in a patient with bulky
disease that regressed slowly over 2 years. One patient
with relapsed, refractory acute promyelocytic leukemia
had gross marrow disease that disappeared 1 month
after transplantation but was still polymerase chain
reaction (PCR)–positive for PML-RARAprotein (reso-
lution of 1:100,000), becoming negative only after 2
months.
HIS likely is mediated by a cytokine storm that is
exquisitely responsive to steroids. In the present
study, it occurred only in patients who received at
least 108 CD31 cells/kg. The associated cytokines
differ from those implicated in GVHD orl CT scans of gallium avid tumor in a patient with diffuse large B cell lym-
mmunotherapy in the absence of any additional therapy. Note the slow
ormed in May 2007 was negative for recurrent disease (data not shown).
tative serial bone marrow results in a patient with AML. At 3 days after
sts and some edema. At 14 days after therapy, resumption of normal
, and the marrow is packed with myeloblasts.
428 Biol Blood Marrow Transplant 15:421-431, 2009G. A. Colvin et al.engraftment syndrome, which include IL-1, IL-2,
IL-8, TNF-a, and IFN-g. HIS also differs from en-
graftment syndrome in terms of negative skin and in-
testinal biopsy results and the absence of
noncardiogenic edema, renal insufficiency, weight
gain, and encephalopathy. HIS may be critical to
our observed tumor responses. The increased pres-
ence of MCP-1 and MIB-1b, which up-regulate
NK cell function and recruitment, suggests that
NK cells play a role in this syndrome, possibly in me-
diating tumor response [34].
Although GVT and GVHD are closely associated,
animal models have shown evidence that antitumor ac-
tivity can be seen with minimal or no obvious GVHD
[19,35,36]. Evidence also exists suggesting that GVT
and GVHD may be separable in alloBMT [37,38]. In
the present study tumor responses were seen with no
evidence of GVHD. This finding is consistent with
failure of engraftment or graft rejection. Dey et al.
[39] reported antitumor responses with chimerism
loss in 9 of 22 patients after nonmyeloablative condi-
tioning and alloBMT. Seven of 9 patients who lost
chimerismwere alive at 2.5 to 5.5 years after transplan-
tation. In this setting, however, there was initial
engraftment, and an initial T cell–mediated GVT
reaction was possible, because T cell chimerism was
present at 2 weeks posttransplantation (. 5%) in 8 of
9 patients. The authors favored the hypothesis that
a host-versus-graft response with associated rejection
promoted the antitumor responses. We favor a similar
hypothesis for the tumor responses noted in our
patients, who never obtained chimerism, although
the 2 trials had major differences. In our study, no
responding patient demonstrated chimerism past
2 weeks posttransplantation, whereas the patients of
Dey et al. [39] had initial engraftment with chimerism
persisting for 21 to 144 days. In our study, there was an
immediate cytokine-related syndrome with both early
and later responses. Although we cannot rule out the
possibility of microchimerism (\5%) with a T cell at-
tack against the tumor, our results demonstrating no
evidence of engraftment or GVHD in responders,
along with different cytokine elevations than are asso-
ciated with classic GVHD/GVT suggest that this is
not the case.
Alternatively, we cannot rule out the possibility
that a graft-versus-host reaction, rather than a host-
versus-graft reaction (ie, graft rejection), was responsi-
ble for awakening host-derived antitumor immunity.
This type of response was suggested by Rajewsky
et al. [40] characterized in a guinea pig model by Ell-
man and coworkers [41,42] and later demonstrated in
a murine model [43].
We speculate that the cells responsible for the
cytokine HIS, which may be related to donor cell re-
jection, altered the host’s tolerance to the tumor and
allowed for a host immune response against the tu-mor. This theory is further supported in murine
models showing that host antidonor immune
responses causing spontaneous or intentionally in-
duced graft rejection by recipient lymphocyte infu-
sions produced antitumor responses against
recipient tumors [44]. In addition, host antidonor
responses capable of eliminating allogeneic donor
WBCs have been shown to be potent and rapidly ac-
tivated, producing almost complete (99.9%) elimina-
tion of donor cells within 3 days after transfusion
[45]. Rapid elimination of large volumes of alloge-
neic donor splenocytes was found to be mediated
by recipient CD81 cells stimulated by donor CD41
T cells. Alloantibodies seem to be responsible for
the elimination of allogeneic donor cells in the ab-
sence of recipient CD81 cells. There is evidence
that the potent host antidonor response could attack
tumors, because of the cross-reactive nature of allor-
eactivity [46-48]. Administering G-CSF before
donor collection potentially enhanced the antigen-
presenting capabilities of the donor WBC’s and
thereby increased the host antidonor responses,
thus increasing the antitumor response. The early
transient responses may well have resulted from lysis
of tumor cells by the infused T cells or NK cells; this
probably does not explain the longer-term responses,
however [49,50]. Other cell types, such as T regula-
tory cells, may have played a role in modulating or
enhancing the responses. The present trial was not
initially designed to separate out this type of infor-
mation. Giving addition infusions at 6- to 8-week in-
tervals would be of interest to evaluate those patients
with transient responses or large tumor burdens.
In summary, our findings indicate that TBI of 100
cGy followed by HLA-haploidentical transplantation
is a biologically active therapy for refractory hemato-
logic disease. The patients with AML and lymphomas
had a high response rate, even when taking into
account that many of the patients treated with this
protocol were enrolled in the Phase I component of
this trial. These data further suggest that persistent
donor chimerism may not be necessary for durable
antitumor response. The rejection of donor-derived
cells in concert with elevated levels of specific cyto-
kines may represent a novel therapeutic approach
for hematologic malignancies.ACKNOWLEDGMENTS
Financial disclosure: This work was supported by
National Institutes of Health (NIH) Grants P20
RR 018757-02, NIDDK K08DK6498-01, and
DK0618585, and by the NIH loan repayment pro-
gram. Additional funding was provided by patient
donations and the Rhode Island Foundation. The
authors thank Mary Falvey, Deborah Morgan, Linda
Biol Blood Marrow Transplant 15:421-431, 2009 429HLA-Haploidentical Cellular ImmunotherapyColvin, Patricia Karwan, and the BMT nursing
team. They also thank Drs Jila Khorsand, Mehrdad
Abedi, Kathy Radie-Keane, Lawrence Lum, Sheila
Pascual, Samuel Chung, Diane Paggioli, Basma
Ali, and Nicola Kouttab for their help with data anal-
ysis, chart review, and patient care.REFERENCES
1. Coley WB. The treatment of malignant tumors by repeated
inoculations of erysipelas, with a report of ten original cases:
1893. Am J Med Sci. 1893;105:487-511.
2. Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor
and cancer research: a historical perspective. Pharmacol Ther.
1994;64:529-564.
3. Kolb H, Mittermuller J, Clemm C. Donor leukocyte transfu-
sions for treatment of recurrent chronic myelogeneous leukemia
in marrow transplant patients. Blood. 1990;76:2462-2465.
4. Bortin MM, Rimm AA, Saltzstein EC. Graft-versus-leukemia:
quantification of adoptive immunotherapy in murine leukemia.
Science. 1973;179:811-813.
5. Odom L, August C, Githen J. Remission of relapsed leukemia
during graft-versus-host reaction. Lancet. 1978;2:537-540.
6. Weiden PL, Flourney N, Thomas ED, et al. Anti-leukemic
effect of graft-versus-host disease in human recipients of alloge-
neic-marrow graft. New Engl J Med. 1979;300:1068-1073.
7. Bradley MB, Sattler RM, Raftopoulos H, et al. Correction of
phenotype in a thalassemia mouse model using a nonmyeloabla-
tive marrow transplantation regimen. Biol Blood Marrow Trans-
plant. 2002;8:453-461.
8. Quesenberry PJ, Stewart MF, Peters S, et al. Engraftment of he-
matopoietic stem cells in nonmyeloablated and myeloablated
hosts. Stem Cells. 1997;15(Suppl 1):167-169.
9. Nilsson SK, Dooner MS, Tiarks CY, et al. Potential and distri-
bution of transplanted hematopoietic stem cells in a nonablated
mouse model. Blood. 1997;89:4013-4020.
10. Quesenberry PJ, Ramshaw H, Crittenden RB, et al. Engraft-
ment of normal murine marrow into nonmyeloablated host
mice. Blood Cells. 1994;20:348-350.
11. Ramshaw HS, Crittenden RB, Dooner M, et al. High levels of
engraftment with a single infusion of bone marrow cells into
normal unprepared mice. Biol Blood Marrow Transplant. 1995;1:
74-80.
12. D’Hondt L, Lambert JF, Damon J, et al. Engraftment of post–
5-fluorouracil murine marrow into minimally myeloablated
(100 cGy) murine hosts. J Hematother Stem Cell Res. 2002;11:
483-490.
13. Stewart FM, Crittenden RB, Lowry PA, et al. Long-term
engraftment of normal and post-5-fluorouracil murine mar-
row into normal nonmyeloablated mice. Blood. 1993;81:
2566-2571.
14. Stewart FM, Zhong S, Wuu J, et al. Lymphohematopoietic
engraftment in minimally myeloablated hosts. Blood. 1998;91:
3681-3687.
15. Colvin GA, Lambert JF, Abedi M, et al. Murine marrow cellu-
larity and the concept of stem cell competition: geographic
and quantitative determinants in stem cell biology. Leukemia.
2004;18:575-583.
16. Ballen KK, Becker PS, Emmons RBV, et al. Low-dose total
body irradiation followed by allogeneic lymphocyte infusion
may induce remission in patients with refractory hematologic
malignancy. Blood. 2002;100:442-450.
17. Sondel PM, Hank JA. Alien-driven diversity and alien-selected
escape: a rationale for allogeneic cancer immunotherapy. Trans-
plant Proc. 1981;13:1915-1921.
18. Bortin MM, Truitt RL, Rimm AA, et al. Graft-versus-leukemia
activity induced by alloimmunization without augmentation of
graft-versus-host activity. Nature. 1979;281:490-491.19. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leuke-
mia reactions after bonemarrow transplantation. Blood. 1990;75:
555-562.
20. Pion S, Fontaine P, BaronC, et al. Immunodominant minor his-
tocompatibility antigens expressed by mouse leukemic cells can
serve as effective targets for T cell immunotherapy. J Clin Invest.
1995;95:1561-1568.
21. Tempelis LD, Wasik MR, Bortin MM. Adoptive immunother-
apy of disseminated malignancies. Role of alien histocompatibil-
ity antigens on cancer cells and effectiveness of cells from
alloimmunized donors. Ric Clin Lab. 1983;13:163-182.
22. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation
for severe combined immunodeficiency with HLA-A, -B, -D,
and -DR incompatible parental marrow cells fractionated
by soybean agglutinin and sheep red blood cells. Blood. 1983;
61:341-348.
23. Ferrara J, Lipton J, Hellman S, et al. Engraftment following
T-cell–depleted marrow transplantation, I: the role of major
and minor histocompatibility barriers. Transplantation. 1987;
43:461-467.
24. Hong R, Horowitz S, Moen R, et al. Thymus and B cell
reconstitution in severe combined immunodeficiency after
transplantation of monoclonal antibody-depleted parental mis-
matched bone marrow. Bone Marrow Transplant. 1987;4:405-
409.
25. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk
acute leukemia with T-cell–depleted stem cells from related
donors with one fully mismatched HLA haplotype. N Engl
J Med. 1998;339:1186-1193.
26. Lacerda JF,Martins C, Carmo JA, et al. Haploidentical stem cell
transplantation with purified CD34 cells after a chemotherapy-
alone conditioning regimen. Biol BloodMarrow Transplant. 2003;
9:633-642.
27. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mis-
matched hematopoietic stem-cell transplantation: a phase II
study in patients with acute leukemia at high risk of relapse.
J Clin Oncol. 2005;23:3447-3454.
28. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab
enables haploidentical human leukocyte antigen-mismatched
hematopoietic stem cell transplantation without ex vivo graft
manipulation. Transplantation. 2005;79:1351-1357.
29. Daly A, McAfee S, Dey B, et al. Nonmyeloablative bonemarrow
transplantation: infectious complications in 65 recipients of
HLA-identical and mismatched transplants. Biol Blood Marrow
Transplant. 2003;9:373-382.
30. Waller EK, Giver CR, Rosenthal H, et al. Facilitating T-cell
immune reconstitution after haploidentical transplantation in
adults. Blood Cells Mol Dis. 2004;33:233-237.
31. Pan L, Delmonte J Jr., Jalonen CK, et al. Pretreatment of donor
mice with granulocyte colony-stimulating factor polarizes donor
T lymphocytes toward type-2 cytokine production and reduces
severity of experimental graft-versus-host disease. Blood. 1995;
86:4422-4429.
32. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-
stimulating factor reduces the capacity of blood mononuclear
cells to induce graft-versus-host disease: impact on blood pro-
genitor cell transplantation. Blood. 1997;90:453-463.
33. Franzke A, Piao W, Lauber J, et al. G-CSF as immune reg-
ulator in T cells expressing the G-CSF receptor: implications
for transplantation and autoimmune diseases. Blood. 2003;102:
734-739.
34. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compati-
bility on engraftment of bone marrow transplants in patients
with leukemia or lymphoma. New Engl J Med. 1989;320:
197-204.
35. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-
versus-host disease while preserving the graft-versus-leukemia
effect of allogeneic T cells. Proc Natl Acad Sci U S A. 1990;87:
5633-5637.
36. Mapara MY, Yong-Mi K, Sheng-PingW, et al. Donor lympho-
cyte infusions mediate superior graft-versus-leukemia effects in
430 Biol Blood Marrow Transplant 15:421-431, 2009G. A. Colvin et al.mixed compared to fully allogeneic chimeras: a critical role for
host antigen-presenting cells. Blood. 2002;100:1903-1909.
37. Spitzer TR,McAfee S, Sackstein R, et al. The intentional induc-
tion of mixed chimerism and achievement of anti-tumor re-
sponses following non-myeloablative conditioning therapy and
HLA-matched donor marrow transplantation for refractory he-
matologic malignancies. Biol Blood Marrow Transplant. 2000;6:
309-320.
38. Dey BR,McAfee S, Colby C, et al. Impact of prophylactic donor
leukocyte infusions on mixed chimerism, graft-versus-host dis-
ease, and antitumor response in patients with advanced hemato-
logic malignancies treated with nonmyeloablative conditioning
and allogenieic bone marrow transplantation. Biol Blood Marrow
Transplant. 2003;9:320-329.
39. Dey BR, McAfee S, Colby CD, et al. Anti-tumor response de-
spite loss of donor chimaerism in patients treated with non-mye-
loablative conditioning and allogeneic stem cell transplantation.
Br J Haematol. 2005;128:351-359.
40. Rajewsky K, Schirrmacher V, Nase S, et al. The requirement of
more than one antigenic determinant for immunogenicity. J Exp
Med. 1969;129:1131-1143.
41. Katz DH, Ellman L, PaulWE, et al. Resistance of guinea pigs to
leukemia following transfer of immunocompetent allogeneic
lymphoid cells. Cancer Res. 1972;32:133-140.
42. Ellman L, Katz DH, Green I, et al. Mechanisms involved in the
antileukemic effect of immunocompetent allogeneic lymphoid
cell transfer. Cancer Res. 1972;32:141-148.APPENDIX 1. Previous Chemotherapy in patients
with Solid Tumors
Unique
Patient ID Diagnosis
Number of
Regimens Chemotherapy Radiation
3 Ewing’s
sarcoma
4 1. CE-DHAP Yes
2. Ifosfamide
3. Busulfan/Melphalan
4. Tandem
Autologous BMT
(TNT)
5 Melanoma 4 1. Tumor vaccine Yes
2. Two agent
chemo unspecified
3. Paclitaxel, cisplatin
4. tumor vaccine,
IL-2, G-CSF
6 Renal cell 0 Yes
7 Breast 4 1. CAF Yes
2. Gemsar/Taxotere/
Platinum
3. Xeloda
4. Paclitaxel/Herceptin
8 Bladder 2 1. Paclitaxel and
Gemcitabine
Yes
2. MVAC
9 Bladder 0 Yes
10 Breast 5 1. TAC Yes
2. Cytoxan
3. Autologous BMT
(ICE)
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Unique
Patient ID Diagnosis
Number of
Regimens Chemotherapy Radiation
4. Herceptin
5. Xeloda
13 Ewing’s
sarcoma
2 1. CAV/ IE Yes
2. Autologous BMT
(Bu/Cy)
20 Breast 4 1. TAC Yes
2. Tamoxifen
3. Autologous BMT
(ICE)
4. Arimidex
4. Arimidex Lung 3 1. Carboplatin/Paclitaxel No
2. Gemcitabine
3. Navalbine
3. Navalbine Prostate 4 1. Lupron/Eulexin No
2. Mitoxantrone/
Novantrone
3. Paclitaxel
4. ATC
24 Renal cell 3 1. IL-2 No
2. Carboxyaminodiazole
3. Thalidomide
28 Eccrine 2 1. Carbo/Paclitaxel
2. Gemcitabine Yes
2. CMF
31 Head &
Neck
4 1. Carboplatin/Paclitaxel Yes
2. Carboplatin/Paclitaxel
3. 5-FU
4. Methotrexate
32 Renal cell 0 No
APPENDIX 2. (Continued )
Unique Number of
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with Hematologic MalignanciesUnique
Patent ID Diagnosis
Number of
Regimens Chemotherapy Radiation
1 Multiple
myeloma
4 1. VAD Yes
2. ICE
3. Rituxan
4. Tandem
Autologous BMT
(melphalan)
2 MDS-AML 6 1. Amifostin No
2. Idarubicin/Ara C
3. Autologous BMT
(BU/Cy)
4. Consolitation
HIDAC
5. Mitoxan trone/VP 16
Myelotarg
4 Multiple
myeloma
6 1. VBMCP Yes
2. Melphaian,
Prednisone
3. Cytoxan
4. Thalidomide
5. Melphalan,
Prednisone
6. DCIE
11 Multiple
myeloma
3 1. VAD Yes
2. Interferon
3. CE/DHAC
12 Lymphoma 3 1. CHOP No
2. Interferon
3. CE/DHAC
14 MDS-AML 1 1. FLAT (Fludarabine/
Ara-C/Topotecan)
No
15 Lymphoma 2 1. CHOP No
2. DHAC
16 AML 5 1. Idarubin/cytarabine No
2. FLAG
3. Mitoxantrone/
etophoside
4. Mylotarg
5. GM-CSF/Ara-C
17 Previous
melanoma
lymphoma
4 1. Temozolamide/
Cisplatin/IL-2/
Interferon
Yes
2. CHOP-Rituximab
3. CE-DHAC
4. Cytoxan
mobilization
18 MDS-AML 1 1. AraC/Idarubicin No
19 Multiple
myeloma
2 1. VAD Yes
2. DCIE
23 Lymphoma 5 1. M-BACOP No
2. CHOP
Patent ID Diagnosis Regimens Chemotherapy Radiation
3. CE/DHAC
4. Auto BMT (CTC)
10 months prior
5. Rituxan
5. Mini ICE
25 Lymphoma 3 1. CHOP No
2. Fludarabine
3. CE/DHAC
26 CML 2 1. HLA identical
transplant
No
2. Gleevec No
27 AML 3 1. ATRA No
2. ATRA
29 Multiple
myeloma
4 1. VAD Yes
2. Autologous BMT
(Melphalan)
39 moths prior
3. Interferon alpha 2B
4. DCIE
30 Lymphoma 5 1. CHOP No
2. CMOP
3. CE/DHAC
4. Syngeneic BMT
(CTC)
5. Mini ICE
33 AML 3 1. ADE No
2. AraC/VP 16
3. AraC/Idarubicin/
Etoposide
34 AML 2 1. Daunorubicin No
2. consolktation
with 5+2
35 MDS-AML 1 1. SQ AraC No
36 AML 3 1. AraC/Idarubicin/Atra No
2. AraC/Idarubicin
3. Arsenic Trioxide
37 ALL 4 1. Vincristine/
methotrexate/
da unorubicin/
prednisone
No
2. Methotrexate
3. cytoxan/prednisone/
daunorubicin
4. Hydrea
38 AML 5 1. Ara C/daunorubicin No
2. AraC/Daunorubicin
3. AraC
4. Myelotarg
5. Melphalan
39 AML 2 1. AraC/idarubicin No
2. AraC/idarubicin
40 AML 3 1. AraC/Daunorubicin No
2. AraC/Daunorubicin
3. AraC/Daunorubicin
41 AML 2 1. AraC/Daunorubicin No
2. High dose AraC(Continued )
